| Long-term outcomes of salvage lymph node dissection for nodal recurrence of prostate cancer after radical prostatectomy: not as good as previously thought CA Bravi, N Fossati, G Gandaglia, N Suardi, E Mazzone, D Robesti, ... European urology 78 (5), 661-669, 2020 | 88 | 2020 |
| Novel insights into the management of oligometastatic prostate cancer: a comprehensive review A Battaglia, G De Meerleer, L Tosco, L Moris, T Van den Broeck, G Devos, ... European urology oncology 2 (2), 174-188, 2019 | 69 | 2019 |
| Neoadjuvant hormonal therapy before radical prostatectomy in high-risk prostate cancer G Devos, W Devlies, G De Meerleer, M Baldewijns, T Gevaert, L Moris, ... Nature Reviews Urology 18 (12), 739-762, 2021 | 49 | 2021 |
| Progression-directed therapy for oligoprogression in castration-refractory prostate cancer C Berghen, S Joniau, P Ost, K Poels, W Everaerts, K Decaestecker, ... European urology oncology 4 (2), 305-309, 2021 | 48 | 2021 |
| The effect of surgical experience on perioperative and oncological outcomes after robot-assisted radical cystectomy with intracorporeal urinary diversion: evidence from a … P Dell’Oglio, E Mazzone, E Lambert, J Vollemaere, M Goossens, ... European urology focus 7 (2), 352-358, 2021 | 39 | 2021 |
| Oncological outcomes of metastasis-directed therapy in oligorecurrent prostate cancer patients following radical prostatectomy G Devos, C Berghen, H Van Eecke, AV Stichele, H Van Poppel, K Goffin, ... Cancers 12 (8), 2271, 2020 | 24 | 2020 |
| Metastasectomy for visceral and skeletal oligorecurrent prostate cancer A Battaglia, G Devos, K Decaestecker, M Witters, L Moris, ... World Journal of Urology 37, 1543-1549, 2019 | 24 | 2019 |
| ARNEO: a randomized phase II trial of neoadjuvant degarelix with or without apalutamide prior to radical prostatectomy for high-risk prostate cancer G Devos, L Tosco, M Baldewijns, T Gevaert, K Goffin, V Petit, C Mai, ... European Urology 83 (6), 508-518, 2023 | 23 | 2023 |
| Assessing the best surgical template at salvage pelvic lymph node dissection for nodal recurrence of prostate cancer after radical prostatectomy: when can bilateral dissection … CA Bravi, N Fossati, G Gandaglia, N Suardi, E Mazzone, D Robesti, ... European urology 78 (6), 779-782, 2020 | 20 | 2020 |
| Clinical actionability of the genomic landscape of metastatic castration resistant prostate cancer W Devlies, M Eckstein, A Cimadamore, G Devos, L Moris, ... Cells 9 (11), 2494, 2020 | 16 | 2020 |
| Preoperative risk-stratification of high-risk prostate cancer: a multicenter analysis B Chys, G Devos, W Everaerts, M Albersen, L Moris, F Claessens, ... Frontiers in oncology 10, 246, 2020 | 14 | 2020 |
| Comparison of peri-operative and early oncological outcomes of robot-assisted vs. open salvage lymph node dissection in recurrent prostate cancer G Devos, T Muilwijk, Y Raskin, V Calderon, L Moris, T Van den Broeck, ... Frontiers in Oncology 9, 781, 2019 | 13 | 2019 |
| Preclinical models in prostate cancer: Resistance to AR targeting therapies in prostate cancer W Devlies, F Handle, G Devos, S Joniau, F Claessens Cancers 13 (4), 915, 2021 | 11 | 2021 |
| Metastasis-directed therapy in castration-refractory prostate cancer (MEDCARE): a non-randomized phase 2 trial C Berghen, S Joniau, K Rans, G Devos, K Poels, K Slabbaert, H Dumez, ... BMC cancer 20, 1-7, 2020 | 10 | 2020 |
| Outcomes of cytoreductive radical prostatectomy for oligometastatic prostate cancer on prostate-specific membrane antigen positron emission tomography: results of a multicenter … P Rajwa, D Robesti, M Chaloupka, F Zattoni, A Giesen, NA Huebner, ... European Urology Oncology, 2023 | 9 | 2023 |
| Neoadjuvant treatment with androgen receptor signaling inhibitors prior to radical prostatectomy: a systematic review G Devos, B Vansevenant, G De Meerleer, A Clinckaert, W Devlies, ... World Journal of Urology, 1-9, 2021 | 9 | 2021 |
| Risk stratification tools in prostate cancer, where do we stand? A Clinckaert, G Devos, E Roussel, S Joniau Translational Andrology and Urology 10 (1), 12, 2021 | 9 | 2021 |
| Have we entered the era of imaging before salvage treatment for recurrent prostate cancer? G Devos, G De Meerleer, S Joniau European Urology 76 (3), 265-267, 2019 | 9 | 2019 |
| Metastasis-directed therapy for oligometastatic urological tumours: still no second-hand news C Berghen, S Joniau, C Vulsteke, M Albersen, G Devos, K Rans, ... ecancermedicalscience 14, 2020 | 7 | 2020 |
| Site-specific relapse patterns of patients with biochemical recurrence following radical prostatectomy assessed by 68Ga-PSMA-11 PET/CT or 11C-Choline PET/CT … G Devos, M Witters, L Moris, T Van den Broeck, C Berghen, W Devlies, ... World journal of urology 39, 399-406, 2021 | 6 | 2021 |
